- 2010.2.3
- Posted Presentation Material(Third Quarter Financial Results for FY2009)
- 2010.2.3
- Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2010 (Unaudited)(PDF790kb)
- 2010.2.3
- Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2010 (PDF1120kb)
- 2010.2.3
- Revision of Financial Forecasts for the Year Ending March 31, 2010 (PDF58kb)
- 2010.1.28
- FDA extends PDUFA action date for STEDESA new drug application(PDF47kb)
- 2010.1.25
- DSP Group Contributes to Haiti Earthquake Relief Efforts(PDF43kb)
- 2010.1.21
- JCR Pharmaceuticals and Dainippon Sumitomo Pharma sign a Letter of Intent for the assignment and acceptance of the growth hormone business(PDF63kb)
- 2010.1.21
- Company Split (Incorporation-type Company Split）of the Company’s Animal Health Products business (PDF89kb)
- 2010.1.21
- Company Split (Absorption-type Company Split） of the Company’s Food & Speciality Products business(PDF92kb)
- 2010.1.20
- Oral hypoglycemic drug METGLUCO obtained a manufacturing and marketing approval (PDF41kb)
- 2010.1.20
- Acquisition of an additional indication of MEROPEN, a carbapenem antibiotic preparation (PDF69kb)
- 2010.1.5
- Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia (PDF71kb)
- 2009.12.18
- SEPRACOR GRANTED PATENT TERM EXTENSION FOR LUNESTA AND PROVIDES UPDATE ON LUNESTA PEDIATRIC STUDIES (PDF47kb)
- 2009.12.15
- Notice of launching of therapeutic agent for hepatocellular carcinoma “MIRIPLA”(PDF53kb)
- 2009.11.27
- Notice of Restructuring (Company Split) of the Company's Non-pharmaceutical Operations
- 2009.11.12
- Posted Presentation Material (Sepracor Inc. Company Overview -November 12, 2009
- 2009.11.12
- Sepracor Factbook 2009 (PDF950kb)
- 2009.10.30
- Posted Presentation Material(Second Quarter Financial Results for FY2009)(PDF234kb)
- 2009.10.29
- Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2010 (Unaudited)(PDF418kb)
- 2009.10.29
- Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2010 (PDF1275kb)
- 2009.10.29
- Difference from Financial Forecasts for the Second Quarter of the Year Ending March 31, 2010 and Revision of Financial Forecasts for the Year Ending March 31, 2010 (PDF79kb)
- 2009.10.21
- Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc. (PDF36kb)
- 2009.10.16
- Therapeutic agent for hepatocellular carcinoma “MIRIPLA” obtained manufacturing and marketing approval (PDF51kb)
- 2009.10.14
- Dainippon Sumitomo Pharma Co., Ltd. Completes Tender Offer for Sepracor Inc.(PDF46kb)
- 2009.9.11
- New OD tablet of AMLODIN by original formulation technology "SUITAB-NEX"(PDF66kb)
- 2009.9.3
- Acquisition of Sepracor Inc.(PDF315kb)
- 2009.9.3
- Dainippon Sumitomo Pharma Co., Ltd. to Acquire U.S.-based Sepracor Inc.(PDF56kb)
- 2009.8.26
- LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY(PDF93kb)
- 2009.8.19
- Posted Annual Report 2009（PDF1,079kb）
- 2009.7.31
- Posted Presentation Material (First Quarter Financial Results for FY2010)
- 2009.7.31
- Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2010 (PDF 364kb)
- 2009.6.26
- Announcement of establishment of a holding company in the U.S.(PDF 41kb)
- 2009.6.19
- Acquisition of an additional indication of AmBisome, a therapeutic agent for systemic fungal infection(PDF 51kb)
- 2009.6.12
- Lurasidone Meeting (PDF 1,177kb)
- 2009.6.5
- Corporate profile update (June 5, 2009)
- 2009.6.3
- STUDY DEMONSTRATING LURASIDONE IS EFFECTIVE IN PATIENTS WITH SCHIZOPHRENIA PUBLISHED IN THE JOURNAL OF CLINICAL PSYCHIATRY(PDF 88kb)
- 2009.5.21
- DAINIPPON SUMITOMO PHARMA ANNOUNCES LURASIDONE PHASE III DATA IN PATIENTS WITH SCHIZOPHRENIA (PDF 107kb)
- 2009.5.12
- Posted Presentation Material (Financial Results for FY2008)(PDF 436kb)
- 2009.5.11
- Summary of Consolidated Financial Results for the Year Ended March 31, 2009 (Unaudited)(PDF307kb)
- 2009.5.11
- Supplementary Financial Data For the Year Ended March 31, 2009 (PDF287kb)
- 2009.4.22
- Acquisition of an additional indication relating to pretreatment for barium enema X-ray examination by concomitant use of NIFLEC and GASMOTIN (PDF 63kb)
- 2009.4.17
- Discontinuation of development of AC-3933, a therapeutic agent for dementia (PDF 37kb)
- 2009.4.9
- Wakunaga appealed to the Supreme Court against the Osaka High Court’s decision (PDF 40kb)
- 2009.3.24
- Announcement of a judgment of the suit(an appeal court decision) (PDF 41kb)
- 2009.3.16
- Launch of "PRONAMID",a gastro-prokinetic agent for dogs (PDF 53kb)
- 2009.3.13
- Notice of launching of a new Parkinson's disease drug "TRERIEF" (PDF 77kb)
- 2009.2.3
- Posted Presentation Material (Third Quarter Financial Results for FY2008)
- 2009.2.3
- Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2009 (PDF 321kb)
- 2009.1.21
- Parkinson's disease drug "TRERIEF" obtained manufacturing and marketing approval(PDF 50kb)
- 2008.11.26
- DSP takes over Kyowa Hakko Kirin’s manufacturing subsidiary in China.(PDF 44kb)
- 2008.11.05
- Posted Presentation Material (Second Quarter Financial Results for FY2008)
- 2008.10.31
- Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2009 (PDF329kb)
- 2008.10.23
- Notice of establishment of Drug Discovery Consortium in neuropsychiatric area(PDF 43kb)
- 2008.9.1
- Posted Annual Report 2008（PDF1,978kb）
- 2008.07.31
- Posted Presentation Material (First Quarter Financial Results for FY2008)
- 2008.07.31
- Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2009 (PDF949kb)
- 2008.06.23
- Notice of launching of Anti-hypertension drug “AVAPRO” (PDF 39kb)
- 2008.05.9
- Posted Presentation Material (Financial Results for FY2007)
- 2008.05.9
- Summary of Consolidated Financial Results for the Year Ended March 31, 2008 (PDF 384kb)
- 2008.05.9
- Supplementary Financial Data for the Year Ended March 31, 2008 (PDF 246kb)
- 2008.05.8
- Novel Therapeutic Agent for Allergic Disorders Discovered in Collaboration with AstraZeneca Progresses to Clinical Development Stage (PDF 35kb)
- 2008.04.21
- Notice of launching of a new antipsychotic LONASEN (PDF 15kb)
- 2008.04.17
- Discontinuation of Development
for an Additional Indication
of Cervical Spondylosis of Limaprost Alfadex,
an Oral Prostaglandin E1 Derivative Preparation (PDF 15kb) - 2008.04.17
- Anti-hypertension drug “Avapro” obtained manufacturing and marketing approval (PDF 38kb)
- 2008.03.28
- Change of Representative Directors (PDF 19kb)
- 2008.02.01
- Overview of Consolidated Financial Results for the First Nine Months of the Year Ending March 31, 2008 (PDF555kb)
- 2007.11.16
- Posted
Presentation Material (First Half Financial Results for FY2007)
(PDF 271kb) - 2007.11.07
- Summary of Interim Consolidated Financial Results For The Year Ending March 31, 2008 (PDF 329kb)
- 2007.11.07
- Supplementary of Interim Consolidated Financial Data For The Year Ending March 31, 2008 (PDF 715kb)
- 2007.11.02
- Dainippon Sumitomo Pharma signs license agreement for a sedative hypnotic agent (PDF43kb)
- 2007.07.30
- Overview of Consolidated Financial Results for the First Three Months of the Year Ending March 31, 2008 (PDF769kb)
- 2007.05.15
- Posted Presentation Material (Financial Results for FY2006)
- 2007.05.10
- Summary of Consolidated Financial Results for The Year Ended March 31, 2007 (PDF 331kb)
- 2007.05.10
- Supplementary Data of Financial Results for The Year Ended March 31, 2007 (PDF 217kb)
- 2007.04.09
- Posted Presentation Material (R&D Meeting)
- 2007.04.05
- Investment in bio-venture fund (PDF 50kb)
- 2007.03.09
- Posted Presentation Material (FY'07-'09 Mid-term Business Plan)
- 2007.02.27
- Mid-term Business Plan (PDF 95kb)
- 2007.02.26
- Notice of Conclusion of Absorption-type Demerger Contact Relating to Diagnostics Business Merger (PDF 67kb)
- 2007.02.14
- Launch of " Replagal3.5 mg "for Anderson-Fabry Disease (PDF 97kb)
- 2007.02.02
- Overview of Consolidated Financial Results for the First Nine Months of the Year Ending March 31, 2007 (PDF782kb)
- 2006.12.13
- Review of overseas development of Lurasidone (SM-13496), an atypical antipsychotic (PDF 61kb)
- 2006.11.28
- Revising domestic development plan of AC-5216, an antianxiety/antidepressant agent (PDF 106kb)
- 2006.11.24
- Notice of Diagnostics Business Merger (PDF 71kb)
- 2006.11.14
- Posted Presentation Material (First Half Financial Results for FY2006)
- 2006.11.08
- Summary of Interim Consolidated Financial Results For The Year Ending March 31, 2007 (PDF 505kb)
- 2006.11.08
- Supplementary of Interim Consolidated Financial Data For The Year Ending March 31, 2007 (PDF 1,658kb)
- 2006.10.27
- Revised March 2007 Interim and Fiscal-Year Financial Estimates
- 2006.08.21
- Dainippon Sumitomo Pharma and Sumitomo Chemical agree with Pfizer on Settlement of Amlodin Lawsuit (PDF53kb)
- 2006.08.03
- Conclusion of an Agreement over Co-promotion of Dops for the Treatment of Orthostatic Hypotension (PDF30kb)
- 2006.07.28
- Overview of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2007 (PDF4,605kb)
- 2006.07.24
- Partnership Agreements Concerning Anti-Hypertension & Hepatocellular Cancer Drugs Reached(PDF57KB)
- 2006.06.19
- English Court denies its jurisdiction over the Amlodin lawsuit brought by Pfizer (PDF16KB)
- 2006.06.15
- Launch of AmBisome 50mg for Intravenous Drip Infusion, a Therapeutic Agent for Systemic Fungal Infection (PDF92kb)
- 2006.05.31
- Dainippon Sumitomo Pharma and Chelsea Therapeutics International Signed Licensing Agreement for Dops for the treatment of orthostatic hypotension (PDF139kb)
- 2006.05.22
- Posted Presentation Material (Financial Results for FY2005, R&D Meeting)
- 2006.05.11
- Summary of Consolidated Financial Results For The Year Ended March 31, 2006(PDF1402kb)
- 2006.05.11
- Results of Re-employment Assistance Program (PDF18kb)
- 2006.04.26
- Notice of Commemorative Dividend (PDF22kb)
- 2006.04.17
- Dainippon Sumitomo Pharma and Eisai Signed Licensing Agreement for “Gasmotin”, a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members (PDF14kb)
- 2006.04.03
- Integration of US Subsidiaries and Renaming of European subsidiary (PDF17kb)
- 2006.03.27
- Pending Expiration of Cooperative Marketing Agreement between Abbott Japan and Dainippon Sumitomo Pharma (PDF18kb)
- 2006.02.24
- Implementation of Re-employment Assistance Program (PDF19kb)
- 2006.02.06
- Overview of Consolidated Financial Results for the First Nine Months of Fiscal Year 2005 (Unaudited)(PDF594kb)
- 2006.02.06
- Announcement of Revised Results Forecasts (PDF51kb)
- 2006.01.25
- Pfizer files lawsuit in England regarding licence for Amlodin (PDF 35kb)
- 2005.10.1
- Dainippon Sumitomo Pharma Website Opened.
